🎉 M&A multiples are live!
Check it out!

Betta Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Betta Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Galapagos, and Julphar.

Betta Pharmaceuticals Overview

About Betta Pharmaceuticals

Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.


Founded

2003

HQ

China
Employees

n/a

Website

bettapharma.com

Financials

LTM Revenue $451M

LTM EBITDA $134M

EV

$3.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Betta Pharmaceuticals Financials

Betta Pharmaceuticals has a last 12-month revenue of $451M and a last 12-month EBITDA of $134M.

In the most recent fiscal year, Betta Pharmaceuticals achieved revenue of $338M and an EBITDA of $93.8M.

Betta Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Betta Pharmaceuticals valuation multiples based on analyst estimates

Betta Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $338M $418M XXX XXX XXX
Gross Profit $285M $290M XXX XXX XXX
Gross Margin 84% 69% XXX XXX XXX
EBITDA $93.8M $120M XXX XXX XXX
EBITDA Margin 28% 29% XXX XXX XXX
Net Profit $52.8M $20.0M XXX XXX XXX
Net Margin 16% 5% XXX XXX XXX
Net Debt n/a $42.0M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Betta Pharmaceuticals Stock Performance

As of April 15, 2025, Betta Pharmaceuticals's stock price is CNY 54 (or $7).

Betta Pharmaceuticals has current market cap of CNY 22.7B (or $3.1B), and EV of CNY 24.2B (or $3.3B).

See Betta Pharmaceuticals trading valuation data

Betta Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.3B $3.1B XXX XXX XXX XXX $0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Betta Pharmaceuticals Valuation Multiples

As of April 15, 2025, Betta Pharmaceuticals has market cap of $3.1B and EV of $3.3B.

Betta Pharmaceuticals's trades at 7.4x LTM EV/Revenue multiple, and 24.8x LTM EBITDA.

Analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Betta Pharmaceuticals and 10K+ public comps

Betta Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.3B XXX XXX XXX
EV/Revenue 8.0x XXX XXX XXX
EV/EBITDA 27.8x XXX XXX XXX
P/E 43.3x XXX XXX XXX
P/E/Growth 1.1x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Betta Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Betta Pharmaceuticals Valuation Multiples

Betta Pharmaceuticals's NTM/LTM revenue growth is 25%

Betta Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Betta Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Betta Pharmaceuticals and other 10K+ public comps

Betta Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 24% XXX XXX XXX XXX
EBITDA Margin 29% XXX XXX XXX XXX
EBITDA Growth 28% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 54% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 23% XXX XXX XXX XXX
G&A Expenses to Revenue 5% XXX XXX XXX XXX
R&D Expenses to Revenue 26% XXX XXX XXX XXX
Opex to Revenue 70% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Betta Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Betta Pharmaceuticals M&A and Investment Activity

Betta Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Betta Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Betta Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Betta Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Betta Pharmaceuticals

When was Betta Pharmaceuticals founded? Betta Pharmaceuticals was founded in 2003.
Where is Betta Pharmaceuticals headquartered? Betta Pharmaceuticals is headquartered in China.
Who is the CEO of Betta Pharmaceuticals? Betta Pharmaceuticals's CEO is Mr. Lieming Ding.
Is Betta Pharmaceuticals publicy listed? Yes, Betta Pharmaceuticals is a public company listed on SHE.
What is the stock symbol of Betta Pharmaceuticals? Betta Pharmaceuticals trades under 300558 ticker.
When did Betta Pharmaceuticals go public? Betta Pharmaceuticals went public in 2016.
Who are competitors of Betta Pharmaceuticals? Similar companies to Betta Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Betta Pharmaceuticals? Betta Pharmaceuticals's current market cap is $3.1B
What is the current revenue of Betta Pharmaceuticals? Betta Pharmaceuticals's last 12-month revenue is $451M.
What is the current EBITDA of Betta Pharmaceuticals? Betta Pharmaceuticals's last 12-month EBITDA is $134M.
What is the current EV/Revenue multiple of Betta Pharmaceuticals? Current revenue multiple of Betta Pharmaceuticals is 7.4x.
What is the current EV/EBITDA multiple of Betta Pharmaceuticals? Current EBITDA multiple of Betta Pharmaceuticals is 24.8x.
What is the current revenue growth of Betta Pharmaceuticals? Betta Pharmaceuticals revenue growth between 2023 and 2024 was 24%.
Is Betta Pharmaceuticals profitable? Yes, Betta Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.